Psilocybin is a psychedelic substance that shows promise as a transdiagnostic treatment approach; research has shown support for its safety and efficacy across multiple mental health populations (Dos Santos et al., 2016; Spriggs et al., 2020). Research has shown that when paired with psychotherapy, a single dose of psilocybin can produce enduring effects on mental wellbeing (Barrett et al., 2020; Young, 2013). Further, given the economic burden of mental illness and that the rates continue to rise (Fofana et al., 2020; Lenzen et al., 2020), trialing the use of psychedelic-assisted psychotherapy in populations with severe mental health problems is crucial to the advancement of psychological science. While psychedelic research in Australia remains limited, there is a psilocybin-assisted psychotherapy trial currently underway in Melbourne, Victoria.
The main objective of the proposed research is to explore the safety and efficacy of targeting psychopathological mechanisms using psilocybin as an adjunct to therapy. We intend to use a double blind randomised placebo-controlled trial to evaluate our outcomes. We are calling upon the public to assist us in reaching our goals. Thank you for your support.
PsychMed operates under National Guidelines and Clinical Governance standards set out in the National Department of Health, in the provision of psychological services to the general public. Additionally, PsychMed adheres to industry standard clinical governance set out by the Australian Psychological Society, and ISO Quality Assurance in its implementation and documentation of management and governance systems.